Pola-BR方案治疗复发/难治弥漫大B细胞淋巴瘤的真实世界研究现状
Current Status of Real-World Studies of Pola-BR in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
摘要: 为方便了解Pola-BR方案在真实世界中治疗复发/难治弥漫大B细胞淋巴瘤的疗效及安全性，本文分析总结了9项回顾性真实世界研究，结果表明使用Pola-BR方案的真实世界数据虽没有GO29365试验的结果理想，但仍然是治疗R/R DLBCL的一种比较好的选择。
Abstract: To facilitate understanding of the efficacy and safety of the Pola-BR in the treatment of relapsed/ refractory diffuse large B-cell lymphoma in the real world, this article analyzes and summarizes nine retrospective real-world studies, and the results suggest that real-world data using the Pola-BR regimen, although not as promising as the results of the GO29365 trial, is still a better option for the treatment of R/R DLBCL.
文章引用：闻一格, 曾瀚庆. Pola-BR方案治疗复发/难治弥漫大B细胞淋巴瘤的真实世界研究现状[J]. 临床医学进展, 2025, 15(2): 1535-1539. https://doi.org/10.12677/acm.2025.152506

参考文献

[1] Garg, M., Takyar, J., Dhawan, A., Saggu, G., Agrawal, N., Hall, A., et al. (2022) Diffuse Large B-Cell Lymphoma (DLBCL): A Structured Literature Review of the Epidemiology, Treatment Guidelines, and Real-World Treatment Patterns. Blood, 140, 12106-12107. [Google Scholar] [CrossRef] 
[2] Sehn, L.H. and Salles, G. (2021) Diffuse Large B-Cell Lymphoma. New England Journal of Medicine, 384, 842-858. [Google Scholar] [CrossRef] [PubMed]
[3] Sehn, L.H., Herrera, A.F., Flowers, C.R., Kamdar, M.K., McMillan, A., Hertzberg, M., et al. (2020) Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 38, 155-165. [Google Scholar] [CrossRef] [PubMed]
[4] Molina, M.S., Hoffman, E.A., Stokes, J., Kummet, N., Smith, K.A., Baker, F., et al. (2021) Regulatory Dendritic Cells Induced by Bendamustine Are Associated with Enhanced Flt3 Expression and Alloreactive T-Cell Death. Frontiers in Immunology, 12, Article 699128. [Google Scholar] [CrossRef] [PubMed]
[5] Payandeh, Z., Bahrami, A.A., Hoseinpoor, R., Mortazavi, Y., Rajabibazl, M., Rahimpour, A., et al. (2019) The Applications of Anti-CD20 Antibodies to Treat Various B Cells Disorders. Biomedicine & Pharmacotherapy, 109, 2415-2426. [Google Scholar] [CrossRef] [PubMed]
[6] Sehn, L.H., Hertzberg, M., Opat, S., Herrera, A.F., Assouline, S.E., Flowers, C., et al. (2020) Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension. Blood, 136, 17-19. [Google Scholar] [CrossRef] 
[7] Segman, Y., Ribakovsky, E., Avigdor, A., Goldhecht, Y., Vainstein, V., Goldschmidt, N., et al. (2020) Outcome of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Treated with Polatuzumab Vedotin-Based Therapy: Real-Life Experience. Leukemia & Lymphoma, 62, 118-124. [Google Scholar] [CrossRef] [PubMed]
[8] Dal, M.S., Ulu, B.U., Uzay, A., Akay, O.M., Beşışık, S., Yenerel, M.N., et al. (2022) Polatuzumab Vedotin, Rituximab, and Bendamustine Combination in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Real-World Data from Turkey. Annals of Hematology, 102, 133-140. [Google Scholar] [CrossRef] [PubMed]
[9] Rattanathammethee, T., Norasetthada, L., Bunworasate, U., Wudhikarn, K., Julamanee, J., Noiperm, P., et al. (2023) Outcomes of Polatuzumab Vedotin-Containing Regimens in Real-World Setting of Relapsed and or Refractory Diffuse Large B-Cell Lymphoma Patients: A Matched-Control Analysis from the Thai Lymphoma Study Group (TLSG). Annals of Hematology, 102, 1887-1895. [Google Scholar] [CrossRef] [PubMed]
[10] Shaw, B., Chung, E., Wellard, C., Yoo, E., Bennett, R., Birks, C., et al. (2024) Poor Outcomes for Trial‐Ineligible Patients Receiving Polatuzumab for Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in Routine Care: An Australian Lymphoma and Related Diseases Registry Project. eJHaem, 5, 325-332. [Google Scholar] [CrossRef] [PubMed]
[11] Liu, Y., Wuxiao, Z., Kong, F., Feng, J., Wu, J., Yao, Z., et al. (2022) A Retrospective Cohort Study of Polatuzumab Vedotin Combined with Immunochemotherapy in Chinese Patients with Relapse/Refractory Diffuse Large B Cell Lymphoma. Annals of Translational Medicine, 10, 1070-1070. [Google Scholar] [CrossRef] [PubMed]
[12] Dimou, M., Papageorgiou, S.G., Stavroyianni, N., et al. (2021) Real‐Life Experience with the Combination of Po-latuzumab Vedotin, Rituximab, and Bendamustine in Aggressive B‐Cell Lymphomas. Hematological Oncology, 39, 336-48. [Google Scholar] [CrossRef] [PubMed]
[13] Vodicka, P., Benesova, K., Janikova, A., Prochazka, V., Belada, D., Mocikova, H., et al. (2022) Polatuzumab Vedotin Plus Bendamustine and Rituximab in Patients with Relapsed/refractory Diffuse Large B‐Cell Lymphoma in the Real World. European Journal of Haematology, 109, 162-165. [Google Scholar] [CrossRef] [PubMed]
[14] Argnani, L., Broccoli, A., Pellegrini, C., Fabbri, A., Puccini, B., Bruna, R., et al. (2022) Real-World Outcomes of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Polatuzumab Vedotin-Based Therapy. HemaSphere, 6, e798. [Google Scholar] [CrossRef] [PubMed]
[15] Northend, M., Wilson, W., Osborne, W., Fox, C.P., Davies, A.J., El-Sharkawi, D., et al. (2022) Results of a United Kingdom Real-World Study of Polatuzumab Vedotin, Bendamustine, and Rituximab for Relapsed/Refractory DLBCL. Blood Advances, 6, 2920-2926. [Google Scholar] [CrossRef] [PubMed]

为你推荐